260 related articles for article (PubMed ID: 15855257)
1. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial.
Mauras N; Pescovitz OH; Allada V; Messig M; Wajnrajch MP; Lippe B;
J Clin Endocrinol Metab; 2005 Jul; 90(7):3946-55. PubMed ID: 15855257
[TBL] [Abstract][Full Text] [Related]
2. The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults.
Cuneo RC; Judd S; Wallace JD; Perry-Keene D; Burger H; Lim-Tio S; Strauss B; Stockigt J; Topliss D; Alford F; Hew L; Bode H; Conway A; Handelsman D; Dunn S; Boyages S; Cheung NW; Hurley D
J Clin Endocrinol Metab; 1998 Jan; 83(1):107-16. PubMed ID: 9435425
[TBL] [Abstract][Full Text] [Related]
3. Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism.
Nørrelund H; Vahl N; Juul A; Møller N; Alberti KG; Skakkebaek NE; Christiansen JS; Jørgensen JO
J Clin Endocrinol Metab; 2000 May; 85(5):1912-7. PubMed ID: 10843174
[TBL] [Abstract][Full Text] [Related]
4. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.
Attanasio AF; Lamberts SW; Matranga AM; Birkett MA; Bates PC; Valk NK; Hilsted J; Bengtsson BA; Strasburger CJ
J Clin Endocrinol Metab; 1997 Jan; 82(1):82-8. PubMed ID: 8989238
[TBL] [Abstract][Full Text] [Related]
5. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
Filipsson Nyström H; Barbosa EJ; Nilsson AG; Norrman LL; Ragnarsson O; Johannsson G
J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study.
Underwood LE; Attie KM; Baptista J;
J Clin Endocrinol Metab; 2003 Nov; 88(11):5273-80. PubMed ID: 14602761
[TBL] [Abstract][Full Text] [Related]
7. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group.
Mauras N; Attie KM; Reiter EO; Saenger P; Baptista J
J Clin Endocrinol Metab; 2000 Oct; 85(10):3653-60. PubMed ID: 11061518
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial.
Hoffman AR; Kuntze JE; Baptista J; Baum HB; Baumann GP; Biller BM; Clark RV; Cook D; Inzucchi SE; Kleinberg D; Klibanski A; Phillips LS; Ridgway EC; Robbins RJ; Schlechte J; Sharma M; Thorner MO; Vance ML
J Clin Endocrinol Metab; 2004 May; 89(5):2048-56. PubMed ID: 15126520
[TBL] [Abstract][Full Text] [Related]
9. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study.
Vahl N; Juul A; Jørgensen JO; Orskov H; Skakkebaek NE; Christiansen JS
J Clin Endocrinol Metab; 2000 May; 85(5):1874-81. PubMed ID: 10843168
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
[TBL] [Abstract][Full Text] [Related]
11. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
[TBL] [Abstract][Full Text] [Related]
12. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
13. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.
Carroll PV; Drake WM; Maher KT; Metcalfe K; Shaw NJ; Dunger DB; Cheetham TD; Camacho-Hübner C; Savage MO; Monson JP
J Clin Endocrinol Metab; 2004 Aug; 89(8):3890-5. PubMed ID: 15292323
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
15. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
Sneppen SB; Hoeck HC; Kollerup G; Sørensen OH; Laurberg P; Feldt-Rasmussen U
Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children.
Johannsson G; Albertsson-Wikland K; Bengtsson BA
J Clin Endocrinol Metab; 1999 Dec; 84(12):4516-24. PubMed ID: 10599711
[TBL] [Abstract][Full Text] [Related]
17. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency.
Boot AM; Engels MA; Boerma GJ; Krenning EP; De Muinck Keizer-Schrama SM
J Clin Endocrinol Metab; 1997 Aug; 82(8):2423-8. PubMed ID: 9253311
[TBL] [Abstract][Full Text] [Related]
18. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth.
Drake WM; Carroll PV; Maher KT; Metcalfe KA; Camacho-Hübner C; Shaw NJ; Dunger DB; Cheetham TD; Savage MO; Monson JP
J Clin Endocrinol Metab; 2003 Apr; 88(4):1658-63. PubMed ID: 12679453
[TBL] [Abstract][Full Text] [Related]
19. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement after GH replacement in GH-deficient adults.
Ezzat S; Fear S; Gaillard RC; Gayle C; Landy H; Marcovitz S; Mattioni T; Nussey S; Rees A; Svanberg E
J Clin Endocrinol Metab; 2002 Jun; 87(6):2725-33. PubMed ID: 12050241
[TBL] [Abstract][Full Text] [Related]
20. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
